Considering our previous findings that SphK2 activity is upregulated in AD brain and promotes Aβ production in neurons, suppression of SphK2/S1P signaling may be a promising multifunctional therapeutic strategy for AD that can act on both astrocytes and neurons. This evidence concerns the gene SPHK2 and Alzheimer disease.